机译:弥漫性大B细胞淋巴瘤患者肿瘤浸润巨噬细胞高表达与预后不良相关
State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Lymphoma Centre, Cancer Center of Sun Yat-sen University, 651 Dong Feng Road East, Guangzhou, 510060, Guangdong, People’s Republic of China;
Department of Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, People’s Republic of China;
State Key Laboratory of Oncology in Southern China, Department of Pathology, Cancer Center of Sun Yat-sen University, Guangzhou, People’s Republic of China;
State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Lymphoma Centre, Cancer Center of Sun Yat-sen University, 651 Dong Feng Road East, Guangzhou, 510060, Guangdong, People’s Republic of China;
State Key Laboratory of Oncology in Southern China, Department of Medical Oncology, Lymphoma Centre, Cancer Center of Sun Yat-sen University, 651 Dong Feng Road East, Guangzhou, 510060, G;
Tumor-associated macrophages; Diffuse large B-cell lymphoma; CHOP; CD68;
机译:弥漫性大B细胞淋巴瘤患者肿瘤浸润巨噬细胞高表达与预后不良相关
机译:高肿瘤PD-L1表达和低PD-1 +或CD8 +肿瘤浸润淋巴细胞是预测中枢神经系统的主要弥漫性大B细胞淋巴瘤的预后差
机译:细胞分裂周期7蛋白的高表达与弥漫性大B细胞淋巴瘤患者的预后不良有关。
机译:患者弥漫性大B细胞淋巴瘤细胞株和血清中microRNA-21的表达及临床意义
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:高肿瘤PD-L1表达和低PD-1 +或CD8 +肿瘤浸润淋巴细胞预示着中枢神经系统原发性弥漫性大B细胞淋巴瘤预后不良
机译:高肿瘤PD-L1表达和低PD-1 +或CD8 +肿瘤浸润淋巴细胞是预测中枢神经系统的主要弥漫性大B细胞淋巴瘤的预后差